Read the Progressive Dairy Canada digital edition

Baytril 100 approved for non-lactating dairy cattle

Published on 30 October 2012

Bayer has received market authorization for Baytril 100 (enrofloxacin) injectable solution for treating bovine respiratory disease (BRD) in non-lactating dairy cattle less than 20 months of age.

This antimicrobial is bactericidal, killing the major culprits responsible for BRD in young cattle: Pasteurella multocida and Mannheimia haemolytica.



The product is concentration-dependent, not time dependent, delivering therapeutic drug concentrations to the lung tissues within two hours of a single subcutaneous dose.

By concentrating where it is needed, Baytril 100 achieves pharmacokinetic and pharmacodynamic drug ratios associated with both the reduction of bacterial resistance selection and improved treatment success.

Available to veterinarians since 2004 for treating recurring BRD in high risk feedlot cattle, Canadian dairy veterinarians now have a new tool to help them in their fight against BRD in dairy replacement herds.

“Left untreated, respiratory disease in cattle impedes growth and increases morbidity, impacting the bottom line,” said Bruce Kilmer, Bayer HealthCare, animal health’s director of technical services and regulatory affairs.

For non-lactating dairy cattle, the ready-to-use, injectable antimicrobial solution may be administered as a single-dose therapy or as a multiple-day therapy. Baytril 100 should not be used as a mass medication.


Please refer to the product label for precautions and warnings.  PD

—From Bayer news release